tiprankstipranks
Jazz Pharmaceuticals (CH:J7Z)
NASDAQ:J7Z
Switzerland Market
J7Z
Jazz Pharmaceuticals
RESEARCH TOOLSreports

Jazz Pharmaceuticals (J7Z) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

J7Z Analyst Ratings

Strong Buy
16Ratings
Strong Buy
15 Buy
1 Hold
0 Sell
Based on 16 analysts giving stock ratings to
Jazz
Pharmaceuticals
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

J7Z Stock 12 Month Forecast

Average Price Target

$212.78
Based on 16 Wall Street analysts offering 12 month price targets for Jazz Pharmaceuticals in the last 3 months. The average price target is $212.78 with a high forecast of $248.44 and a low forecast of $185.32. The average price target represents a ― change from the last price of ―.
eyJuYXZpZ2F0b3IiOnsiZGlzYWJsZWQiOnRydWV9LCJleHBvcnRpbmciOnsiZW5hYmxlZCI6ZmFsc2V9LCJ0aXRsZSI6eyJ0ZXh0IjpudWxsfSwiY2hhcnQiOnsiaGVpZ2h0IjoyMDAsInN0eWxlIjp7ImZvbnRGYW1pbHkiOiJSb2JvdG8gRmxleCwgLWFwcGxlLXN5c3RlbSwgQmxpbmtNYWNTeXN0ZW1Gb250LCBTZWdvZSBVSSwgUm9ib3RvLCBIZWx2ZXRpY2EsIEFyaWFsLCBzYW5zLXNlcmlmLCBBcHBsZSBDb2xvciBFbW9qaSwgU2Vnb2UgVUkgRW1vamksIFNlZ29lIFVJIFN5bWJvbCIsImZvbnRXZWlnaHQiOiI0MDAiLCJjb2xvciI6IiM1ZDVkNWUifX0sInlBeGlzIjp7ImxhYmVscyI6eyJzdHlsZSI6eyJjb2xvciI6ImluaGVyaXQifX0sInZpc2libGUiOmZhbHNlfSwicGxvdE9wdGlvbnMiOnsic2VyaWVzIjp7InN0YXRlcyI6eyJpbmFjdGl2ZSI6eyJvcGFjaXR5IjoxfX19fSwieEF4aXMiOnsibGFiZWxzIjp7InN0eWxlIjp7ImNvbG9yIjoiaW5oZXJpdCJ9fSwidmlzaWJsZSI6ZmFsc2V9LCJsZWdlbmQiOnsic3ltYm9sUmFkaXVzIjowLCJzeW1ib2xQYWRkaW5nIjo0LCJzeW1ib2xIZWlnaHQiOjE0LCJib3JkZXJXaWR0aCI6MCwic3ltYm9sV2lkdGgiOjE0LCJhbGlnbiI6ImxlZnQiLCJ2ZXJ0aWNhbEFsaWduIjoiYm90dG9tIiwiZW5hYmxlZCI6ZmFsc2V9LCJ0b29sdGlwIjp7ImJhY2tncm91bmRDb2xvciI6IndoaXRlIn0sImNyZWRpdHMiOnsiZW5hYmxlZCI6ZmFsc2V9LCJhY2Nlc3NpYmlsaXR5Ijp7ImRlc2NyaXB0aW9uIjoiIn0sInNlcmllcyI6W3sidHlwZSI6ImFyZWEiLCJkYXRhIjpbXX1dfQ==
Highest Price Target$248.44Average Price Target$212.78Lowest Price Target$185.32
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
UBS Analyst forecast on CH:J7Z
Ashwani Verma
UBS
UBS
CHF248.44
Buy
―
Reiterated
07/01/26
Analysts Offer Insights on Healthcare Companies: Jazz Pharmaceuticals (NASDAQ: JAZZ), BeOne Medicines (NASDAQ: ONC) and Zevra Therapeutics (NASDAQ: ZVRA)
Needham Analyst forecast on CH:J7Z
Ami Fadia
Needham
Needham
CHF206.36
Buy
―
Reiterated
06/29/26
Analysts' Top Healthcare Picks: Amgen (AMGN), BridgeBio Pharma (BBIO)
Truist Financial Analyst forecast on CH:J7Z
Gregory Renza
Truist Financial
Truist Financial
―
Buy
―
Reiterated
06/18/26
Analysts Offer Insights on Healthcare Companies: Sionna Therapeutics, Inc. (NASDAQ: SION), Celldex (NASDAQ: CLDX) and Jazz Pharmaceuticals (NASDAQ: JAZZ)
Jefferies Analyst forecast on CH:J7Z
Unknown Analyst
Jefferies
Not Ranked
Jefferies
CHF214.45
Buy
―
Reiterated
06/16/26
Jefferies Keeps Their Buy Rating on Jazz Pharmaceuticals (JAZZ)
Piper Sandler Analyst forecast on CH:J7Z
David Amsellem
Piper Sandler
Piper Sandler
CHF243.59
Buy
―
Reiterated
06/16/26
Piper Sandler Reaffirms Their Buy Rating on Jazz Pharmaceuticals (JAZZ)
TD Cowen Analyst forecast on CH:J7Z
Joseph Thome
TD Cowen
TD Cowen
CHF222.55
Buy
―
Reiterated
06/12/26
Analysts Offer Insights on Healthcare Companies: Jazz Pharmaceuticals (NASDAQ: JAZZ) and Edwards Lifesciences (NYSE: EW)
Bank of America Securities Analyst forecast on CH:J7Z
Jason Gerberry
Bank of America Securities
Bank of America Securities
CHF248.44
Buy
―
Reiterated
06/10/26
Analysts Offer Insights on Healthcare Companies: Cigna (NYSE: CI), Jazz Pharmaceuticals (NASDAQ: JAZZ) and Lifestance Health Group (NASDAQ: LFST)
J.P. Morgan Analyst forecast on CH:J7Z
Jessica Fye
J.P. Morgan
J.P. Morgan
―
Buy
―
Reiterated
06/02/26
Jessica Fye Reaffirms Buy on Jazz Pharmaceuticals, Citing Blockbuster Potential for Zanidatamab in First-Line HER2-Positive Gastric and Esophageal Cancers
Barclays Analyst forecast on CH:J7Z
Etzer Darout
Barclays
Barclays
CHF189.37→CHF204.74
Buy
―
Reiterated
05/27/26
Jazz Pharmaceuticals (JAZZ) Receives a Buy from Barclays
RBC Capital Analyst forecast on CH:J7Z
Leonid Timashev
RBC Capital
RBC Capital
CHF157.8→CHF208.79
Buy
―
Assigned
05/06/26
Jazz Pharmaceuticals (JAZZ) Gets a Buy from RBC Capital
Stifel Nicolaus Analyst forecast on CH:J7Z
Annabel Samimy
Stifel Nicolaus
Stifel Nicolaus
CHF186.13
Buy
―
Reiterated
05/06/26
Analysts Offer Insights on Healthcare Companies: Jazz Pharmaceuticals (NASDAQ: JAZZ), SOPHiA GENETICS (NASDAQ: SOPH) and Solventum Corporation (NYSE: SOLV)
Wells Fargo Analyst forecast on CH:J7Z
Mohit Bansal
Wells Fargo
Wells Fargo
CHF202.31→CHF214.45
Buy
―
Reiterated
05/06/26
Wells Fargo Keeps Their Buy Rating on Jazz Pharmaceuticals (JAZZ)
Raymond James Analyst forecast on CH:J7Z
Tiago Fauth
Raymond James
Raymond James
CHF193.41
Buy
―
Reiterated
05/06/26
Raymond James Reaffirms Their Buy Rating on Jazz Pharmaceuticals (JAZZ)
Robert W. Baird Analyst forecast on CH:J7Z
Brian Skorney
Robert W. Baird
Robert W. Baird
CHF169.13→CHF203.93
Buy
―
Reiterated
05/06/26
Jazz Pharmaceuticals price target raised to $252 from $209 at BairdJazz Pharmaceuticals price target raised to $252 from $209 at Baird
Morgan Stanley Analyst forecast on CH:J7Z
Sean Laaman
Morgan Stanley
Morgan Stanley
CHF182.89→CHF198.27
Buy
―
Reiterated
05/05/26
Analysts Conflicted on These Healthcare Names: Jazz Pharmaceuticals (NASDAQ: JAZZ), Dianthus Therapeutics (NASDAQ: DNTH) and Waters (NYSE: WAT)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
UBS Analyst forecast on CH:J7Z
Ashwani Verma
UBS
UBS
CHF248.44
Buy
―
Reiterated
07/01/26
Analysts Offer Insights on Healthcare Companies: Jazz Pharmaceuticals (NASDAQ: JAZZ), BeOne Medicines (NASDAQ: ONC) and Zevra Therapeutics (NASDAQ: ZVRA)
Needham Analyst forecast on CH:J7Z
Ami Fadia
Needham
Needham
CHF206.36
Buy
―
Reiterated
06/29/26
Analysts' Top Healthcare Picks: Amgen (AMGN), BridgeBio Pharma (BBIO)
Truist Financial Analyst forecast on CH:J7Z
Gregory Renza
Truist Financial
Truist Financial
―
Buy
―
Reiterated
06/18/26
Analysts Offer Insights on Healthcare Companies: Sionna Therapeutics, Inc. (NASDAQ: SION), Celldex (NASDAQ: CLDX) and Jazz Pharmaceuticals (NASDAQ: JAZZ)
Jefferies Analyst forecast on CH:J7Z
Unknown Analyst
Jefferies
Not Ranked
Jefferies
CHF214.45
Buy
―
Reiterated
06/16/26
Jefferies Keeps Their Buy Rating on Jazz Pharmaceuticals (JAZZ)
Piper Sandler Analyst forecast on CH:J7Z
David Amsellem
Piper Sandler
Piper Sandler
CHF243.59
Buy
―
Reiterated
06/16/26
Piper Sandler Reaffirms Their Buy Rating on Jazz Pharmaceuticals (JAZZ)
TD Cowen Analyst forecast on CH:J7Z
Joseph Thome
TD Cowen
TD Cowen
CHF222.55
Buy
―
Reiterated
06/12/26
Analysts Offer Insights on Healthcare Companies: Jazz Pharmaceuticals (NASDAQ: JAZZ) and Edwards Lifesciences (NYSE: EW)
Bank of America Securities Analyst forecast on CH:J7Z
Jason Gerberry
Bank of America Securities
Bank of America Securities
CHF248.44
Buy
―
Reiterated
06/10/26
Analysts Offer Insights on Healthcare Companies: Cigna (NYSE: CI), Jazz Pharmaceuticals (NASDAQ: JAZZ) and Lifestance Health Group (NASDAQ: LFST)
J.P. Morgan Analyst forecast on CH:J7Z
Jessica Fye
J.P. Morgan
J.P. Morgan
―
Buy
―
Reiterated
06/02/26
Jessica Fye Reaffirms Buy on Jazz Pharmaceuticals, Citing Blockbuster Potential for Zanidatamab in First-Line HER2-Positive Gastric and Esophageal Cancers
Barclays Analyst forecast on CH:J7Z
Etzer Darout
Barclays
Barclays
CHF189.37→CHF204.74
Buy
―
Reiterated
05/27/26
Jazz Pharmaceuticals (JAZZ) Receives a Buy from Barclays
RBC Capital Analyst forecast on CH:J7Z
Leonid Timashev
RBC Capital
RBC Capital
CHF157.8→CHF208.79
Buy
―
Assigned
05/06/26
Jazz Pharmaceuticals (JAZZ) Gets a Buy from RBC Capital
Stifel Nicolaus Analyst forecast on CH:J7Z
Annabel Samimy
Stifel Nicolaus
Stifel Nicolaus
CHF186.13
Buy
―
Reiterated
05/06/26
Analysts Offer Insights on Healthcare Companies: Jazz Pharmaceuticals (NASDAQ: JAZZ), SOPHiA GENETICS (NASDAQ: SOPH) and Solventum Corporation (NYSE: SOLV)
Wells Fargo Analyst forecast on CH:J7Z
Mohit Bansal
Wells Fargo
Wells Fargo
CHF202.31→CHF214.45
Buy
―
Reiterated
05/06/26
Wells Fargo Keeps Their Buy Rating on Jazz Pharmaceuticals (JAZZ)
Raymond James Analyst forecast on CH:J7Z
Tiago Fauth
Raymond James
Raymond James
CHF193.41
Buy
―
Reiterated
05/06/26
Raymond James Reaffirms Their Buy Rating on Jazz Pharmaceuticals (JAZZ)
Robert W. Baird Analyst forecast on CH:J7Z
Brian Skorney
Robert W. Baird
Robert W. Baird
CHF169.13→CHF203.93
Buy
―
Reiterated
05/06/26
Jazz Pharmaceuticals price target raised to $252 from $209 at BairdJazz Pharmaceuticals price target raised to $252 from $209 at Baird
Morgan Stanley Analyst forecast on CH:J7Z
Sean Laaman
Morgan Stanley
Morgan Stanley
CHF182.89→CHF198.27
Buy
―
Reiterated
05/05/26
Analysts Conflicted on These Healthcare Names: Jazz Pharmaceuticals (NASDAQ: JAZZ), Dianthus Therapeutics (NASDAQ: DNTH) and Waters (NYSE: WAT)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Jazz Pharmaceuticals

3 Months
Joseph ThomeTD Cowen
Success Rate
13/20 ratings generated profit
65%
Average Return
+6.62%
Copying Joseph Thome's trades and holding each position for 3 Months would result in 65.00% of your transactions generating a profit, with an average return of +6.62% per trade.
1 Year
Joseph ThomeTD Cowen
Success Rate
19/20 ratings generated profit
95%
Average Return
+41.02%
Copying Joseph Thome's trades and holding each position for 1 Year would result in 95.00% of your transactions generating a profit, with an average return of +41.02% per trade.
2 Years
Joseph ThomeTD Cowen
Success Rate
20/20 ratings generated profit
100%
Average Return
+73.16%
Copying Joseph Thome's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +73.16% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

J7Z Analyst Recommendation Trends

Rating
Mar 26
Apr 26
May 26
Jun 26
Jul 26
Strong Buy
2
0
0
0
0
Buy
27
22
25
31
26
Hold
0
0
3
5
5
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
29
22
28
36
31
In the current month, J7Z has received 26 Buy Ratings, 5 Hold Ratings, and 0 Sell Ratings. J7Z average Analyst price target in the past 3 months is 212.78.
Each month's total comprises the sum of three months' worth of ratings.

J7Z Financial Forecast

J7Z Earnings Forecast

Next quarter’s earnings estimate for J7Z is $4.95 with a range of $4.44 to $5.68. The previous quarter’s EPS was $5.09. J7Z beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year J7Z has Performed in-line its overall industry.
Next quarter’s earnings estimate for J7Z is $4.95 with a range of $4.44 to $5.68. The previous quarter’s EPS was $5.09. J7Z beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year J7Z has Performed in-line its overall industry.

J7Z Sales Forecast

Next quarter’s sales forecast for J7Z is $891.14M with a range of $856.89M to $928.37M. The previous quarter’s sales results were $858.42M. J7Z beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year J7Z has Performed in-line its overall industry.
Next quarter’s sales forecast for J7Z is $891.14M with a range of $856.89M to $928.37M. The previous quarter’s sales results were $858.42M. J7Z beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year J7Z has Performed in-line its overall industry.

J7Z Stock Forecast FAQ

What is CH:J7Z’s average 12-month price target, according to analysts?
Based on analyst ratings, Jazz Pharmaceuticals’s 12-month average price target is 212.78.
    What is CH:J7Z’s upside potential, based on the analysts’ average price target?
    Currently there's no upside potential for CH:J7Z, based on the analysts’ average price target.
    Can I see which stocks the top-ranking analysts are rating?
    Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
      How can I follow the stock ratings of top Wall Street analysts?
      Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
        Is Jazz Pharmaceuticals a Buy, Sell or Hold?
        Jazz Pharmaceuticals has a consensus rating of Strong Buy, which is based on 15 buy ratings, 1 hold ratings and 0 sell ratings.
          What is Jazz Pharmaceuticals’s share price target?
          The average share price target for Jazz Pharmaceuticals is 212.78. This is based on 16 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
          The highest analyst share price target is $248.44 ,and the lowest forecast is $185.32. The average share price target represents N/A Increase from the current price of N/A.
            What do analysts say about Jazz Pharmaceuticals?
            Jazz Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 16 Wall Streets Analysts.
              How can I buy shares of Jazz Pharmaceuticals?
              To buy shares of CH:J7Z, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.